secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001493152-23-035743
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics acquires Odyssey's brain disorder assets for $1M cash and 8M convertible preferred shares
--------------------------------------------------------------------------------

- Deal consideration: $1M cash (half due at signing, half at closing or sooner) and 8M shares of Series F Preferred Stock convertible 1:1 into common after shareholder approvals.
- Assets include drug candidates for mild traumatic brain injury (concussion) and Niemann Pick Disease Type C, plus a proprietary powder formulation and nasal delivery device.
- Closing requires Oragenics shareholders to increase authorized common stock from ~4.17M to 350M shares and approve the conversion; Oragenics must also have at least $5M cash at closing.
- Closing expected end of Q4 2023; Oragenics has previously struggled to obtain a quorum at shareholder meetings, creating execution risk.
- Oragenics plans to present the shareholder approvals at its annual meeting scheduled for December 14, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223035743/0001493152-23-035743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223035743/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-035743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer